Pregabalin Capsule
Product Images NDC 68788-7656

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 68788-7656). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pregabalin Caps 300mg 500s Count

Pregabalin Capsules 300 mg generic label for Lyrica showing preferred pharmaceuticals and ScieGen Pharmaceuticals. The label includes dosage instructions in English and Spanish, storage instructions, federal law caution, and barcode. The capsules are described as orange and white with imprint SG 357.*

FDA Label Image

Figure 1 (Pregabalin Fig01)

A line graph showing percent of patients improved versus percent improvement in pain from baseline for Pregabalin at doses of 25 mg, 100 mg, and 200 mg taken three times a day, compared to placebo. The graph illustrates patient response rates across different pain improvement levels.*

FDA Label Image

Figure 2 (Pregabalin Fig02)

A line graph comparing the percent improvement in pain from baseline for patients treated with Pregabalin 300 mg (100 mg three times a day) versus placebo. The x-axis represents percent improvement in pain, and the y-axis represents the percent of patients improved, showing higher improvement rates in the Pregabalin group.*

FDA Label Image

Figure 3 (Pregabalin Fig03)

Line graph displaying the percent of patients improved versus percent improvement in pain from baseline. It compares four groups: Pregabalin 300 mg twice daily, Pregabalin 150 mg twice daily, Pregabalin 75 mg twice daily, and placebo. The graph shows increasing patient improvement with higher doses of Pregabalin compared to placebo.*

FDA Label Image

Figure 4 (Pregabalin Fig04)

A line graph depicting percent of patients improved versus percent improvement in pain from baseline. It compares three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. Improvement trends show higher efficacy in the 200 mg group compared to 100 mg and placebo.*

FDA Label Image

Figure 5 (Pregabalin Fig05)

A line graph depicting the percent improvement in pain from baseline on the x-axis versus the percent of patients improved on the y-axis for Pregabalin 50 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The graph compares the efficacy of these treatments over a range of pain improvement percentages.*

FDA Label Image

Figure 6 (Pregabalin Fig06)

A bar chart showing responder rates (%) in two studies, Study E1 and Study E3, comparing placebo and varying dosages of pregabalin. Study E1 ranges from placebo to 600 mg/day in BID dosing, showing increasing responder rates up to 51%. Study E3 compares placebo to 300 mg/day BID and 600 mg/day TID, with responder rates up to 49%. Statistically significant differences versus placebo are indicated with an asterisk.*

FDA Label Image

Figure 7 (Pregabalin Fig07)

A dose-response plot illustrating median percent reduction in seizures from baseline across different doses (mg/day) for four studies labeled E1 BID, E2 TID, E3 BID, and E3 TID. The graph shows increasing seizure reduction with higher doses, with significant p-values noted at various dose points. Placebo dose is indicated at zero.*

FDA Label Image

Figure 9 (Pregabalin Fig08)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline, comparing Pregabalin 800 mg, 450 mg, and 300 mg daily doses to placebo. The graph shows declining improvement percentages as percent improvement in pain increases, with distinct lines for each dosage and placebo.*

FDA Label Image

Figure 10 (Pregabalin Fig09)

A line chart comparing the estimated percentage of subjects without LTR (loss to response) over 180 days for Pregabalin versus Placebo. The y-axis shows the percentage from 0% to 100%, and the x-axis shows days from 0 to 180. Pregabalin is represented by a solid line, and Placebo by a dashed line, with Pregabalin showing a higher percentage of subjects without LTR over time.*

FDA Label Image

Figure 11 (Pregabalin Fig10)

A line graph comparing the percent of subjects improved over time between Pregabalin and placebo groups. The x-axis represents percent improved from baseline to week 12 BOCF, ranging from 0 to 100, and the y-axis shows percent of subjects improved, from 0 to 100, with two lines depicting Pregabalin and placebo outcomes.*

FDA Label Image

Figure 12 (Pregabalin Fig11)

A line graph comparing the percent of subjects improved between Pregabalin and Placebo groups over a range of percent improvement from baseline to Week 16 BOCF. The x-axis represents percent improvement from baseline to Week 16, and the y-axis shows the percent of subjects improved. Two lines represent data for Pregabalin and Placebo, with Pregabalin consistently showing a higher percentage of subjects improved.*

FDA Label Image

Cockcroft And Gault Equation (Pregabalin Formula)

The image shows a mathematical formula for calculating creatinine clearance (CLcr), which involves age, weight, serum creatinine levels, and a factor adjustment for female patients. It is a text panel containing a pharmacokinetic or clinical calculation.*

FDA Label Image

Chemical Structure (Pregabalin Str)

Chemical structure diagram of pregabalin, showing its molecular framework with labeled functional groups including an amino group and a carboxylic acid group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.